RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07475026, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Men with partners of childbearing potential must agree to use effective contraception during the study and for 6 months after the end of study treatment.

    Inclusion criterion 25

  3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.

    Inclusion criterion 3

  4. Absolute neutrophil count (ANC) ≥ 1,500/mm³

    Inclusion criterion 11

    Platelet count ≥ 100,000/mm³

    Inclusion criterion 12

    Hemoglobin ≥ 5.6 mmol/L (9 g/dL)

    Inclusion criterion 13

    Serum creatinine (SCr) ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula)

    Inclusion criterion 15

    Total bilirubin (TBIL) ≤ 1.5 × ULN

    Inclusion criterion 16

    AST and/or ALT ≤ 2.5 × ULN

    Inclusion criterion 17

    International normalized ratio (INR) ≤ 1.5 × ULN

    Inclusion criterion 20

    Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN

    Inclusion criterion 21

    Prothrombin time (PT) ≤ 1.5 × ULN

    Inclusion criterion 22

  5. At least one measurable lesion per RECIST v1.1.

    Inclusion criterion 7

  6. Known cholangiocarcinoma, sarcomatoid HCC, mixed hepatocellular-cholangiocarcinoma, or fibrolamellar carcinoma; or any other active malignancy besides HCC within the past 5 years or concurrently (except cured basal cell carcinoma of the skin and cervical carcinoma in situ).

    Exclusion criterion 2

    Congenital or acquired immunodeficiency, such as HIV infection.

    Exclusion criterion 17

  7. Women of childbearing potential must agree to use effective contraception (e.g., intrauterine device, oral contraceptives, or condoms) during study treatment and for 6 months after the last dose; must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding.

    Inclusion criterion 24

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07475026, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily participates in this study and provides written informed consent.
  • Aged 18 to 75 years, inclusive; male or female.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.
  • Child-Pugh class A liver function.
  • China Liver Cancer (CNLC) stage Ib to IIa.
  • Histologically/cytologically confirmed HCC, or clinically diagnosed primary hepatocellular carcinoma according to accepted diagnostic criteria, with lesions meeting the criteria for surgical resection as defined in the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 edition).
  • At least one measurable lesion per RECIST v1.1.
  • Estimated life expectancy ≥ 6 months.
  • Adequate major organ function as defined below, without transfusion of any blood components or use of hematopoietic growth factors within 14 days prior to assessment:
  • Hematology
  • Absolute neutrophil count (ANC) ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin ≥ 5.6 mmol/L (9 g/dL)
  • Hepatic and renal function
  • Serum creatinine (SCr) ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula)
  • Total bilirubin (TBIL) ≤ 1.5 × ULN
  • AST and/or ALT ≤ 2.5 × ULN
  • Urine protein < 2+; if urine protein is ≥ 2+, 24-hour urine protein must be ≤ 1 g.
  • Adequate coagulation function, with no active bleeding and no thrombotic disease:
  • International normalized ratio (INR) ≤ 1.5 × ULN
  • Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
  • Prothrombin time (PT) ≤ 1.5 × ULN
  • Contraception requirements:
  • Women of childbearing potential must agree to use effective contraception (e.g., intrauterine device, oral contraceptives, or condoms) during study treatment and for 6 months after the last dose; must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding.
  • Men with partners of childbearing potential must agree to use effective contraception during the study and for 6 months after the end of study treatment.
  • Demonstrates good compliance and is able/willing to complete required follow-up.

Exclusion Criteria:

  • Prior antitumor therapy for the current HCC, including radiotherapy, chemotherapy, concurrent chemoradiotherapy, other locoregional therapies (e.g., TACE, HAIC), or prior immunotherapy or targeted therapy.

Note: Patients who developed recurrence after prior surgery may be enrolled; if prior postoperative adjuvant therapy was given, enrollment is allowed only if ≥6 months have elapsed since completion of adjuvant therapy.

  • Known cholangiocarcinoma, sarcomatoid HCC, mixed hepatocellular-cholangiocarcinoma, or fibrolamellar carcinoma; or any other active malignancy besides HCC within the past 5 years or concurrently (except cured basal cell carcinoma of the skin and cervical carcinoma in situ).
  • Hypertension inadequately controlled with antihypertensive therapy (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg); or history of hypertensive crisis or hypertensive encephalopathy.
  • Known hypersensitivity to macromolecular protein preparations, or known allergy to tislelizumab, lenvatinib, or any of their excipients.
  • Any active autoimmune disease or history of autoimmune disease (including but not limited to autoimmune hepatitis, interstitial pneumonitis, uveitis, enteritis/colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism). Patients with vitiligo, or asthma that completely resolved in childhood and requires no intervention in adulthood, may be eligible. Patients with asthma requiring medical intervention with bronchodilators are not eligible.
  • Use of immunosuppressive agents or systemic, or absorbable topical, corticosteroids for immunosuppressive purposes (dose >10 mg/day prednisone or equivalent) within 2 weeks prior to enrollment.
  • Symptomatic ascites or pleural effusion requiring therapeutic paracentesis or drainage.
  • Uncontrolled clinically significant cardiac symptoms or disease, including any of the following:
  • New York Heart Association (NYHA) class > II heart failure
  • Unstable angina
  • Myocardial infarction within 1 year
  • Clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention
  • Within the past 3 months, presence of gastrointestinal conditions such as esophageal varices, active gastric or duodenal ulcer, ulcerative colitis, portal hypertension, or active bleeding from an unresected tumor; or any other condition judged by the investigator to confer a risk of gastrointestinal bleeding or perforation.
  • History of or current severe bleeding (within 3 months, bleeding volume >30 mL), hemoptysis (within 4 weeks, >5 mL fresh blood), or thromboembolic events within 12 months (including stroke and/or transient ischemic attack).
  • Active infection, or unexplained fever >38.5°C during screening or prior to first dose (fever judged by the investigator to be tumor-related is allowed).
  • Objective evidence of prior or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severely impaired pulmonary function.
  • Congenital or acquired immunodeficiency, such as HIV infection.
  • Receipt of a live vaccine within 4 weeks prior to study drug administration, or anticipated need for live vaccination during the study.
  • Known history of psychotropic drug abuse, alcoholism, or illicit drug use.
  • Anticipated inability or unwillingness to comply with required study procedures, assessments, and follow-up (including completion of standard-of-care evaluations not covered by the study), as judged by the investigator.
  • Any other condition that, in the investigator's judgment, makes the subject unsuitable for the study, including factors that may lead to premature study discontinuation (e.g., other serious diseases [including psychiatric disorders] requiring concomitant treatment, severe laboratory abnormalities, or family/social factors that may compromise subject safety or the collection of data and specimens).

Quoted from ClinicalTrials.gov, NCT07475026, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07475026, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07475026